Previous 10 | Next 10 |
INDIANAPOLIS and MOL, Belgium , Nov. 24, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, and Studiecentrum voor Kernenergie/Centre d’Etude de l’Energ...
POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations Register online at https://hub.pointbiopharma.com/dec2021 INDIANAPOLIS, Nov. 22, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc....
POINT Biopharma Global (NASDAQ:PNT): Q3 GAAP EPS of -$0.19. Cash and Cash Equivalents of $252.82M Press Release For further details see: POINT Biopharma Global reports Q3 results
Initiated randomization phase of Phase 3 SPLASH study of PNT2002 in patients with metastatic castration-resistant prostate cancer (mCRPC) Expanded FAP alpha inhibitor platform and on track to file an IND/CTA for PNT2004's lead, PNT6555, in the first half of 2022 Complete...
INDIANAPOLIS and TORONTO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, and IONETIX Corporation, a leading cyclotron technology and isotope manufacturin...
POINT Biopharma (NASDAQ:PNT) and Kinectrics announce a long-term supply agreement for Ytterbium-176 (Yb-176) to support the company's in-house no-carrier added Lutetium-177 (n.c.a. Lu-177) production program. The input material for creating n.c.a. Lu-177 is Ytterbium-176 (Yb-176): a...
POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations on Dec 6, 2021 – register online at https://hub.pointbiopharma.com/dec2021 INDIANAPOLIS and TORONTO, Oct. 29, 2021 (GLOBE NEWSWIRE) ...
Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models Initiation of a Phase 1 therapeutic clinical trial planned for 1H2022 INDIANAPOLIS, Sept. 28, 2021 (GLOBE NEWSWIRE) -...
25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21 INDIANAPOLIS, Indiana, Sept. 23, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASD...
Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-α (Rosopatamab-225Ac) in combination with PNT2002 for Progressive Metastatic Castration-Resistant Prostate Cancer Phase I/II investigator-Initiated Trial to be conducted at Weill Corn...
News, Short Squeeze, Breakout and More Instantly...
POINT Biopharma Global Inc. Company Name:
PNT Stock Symbol:
NASDAQ Market:
POINT Biopharma Global Inc. Website:
NORTHAMPTON, MA / ACCESSWIRE / June 25, 2024 / Pentair Greg Claffey, Group President, Pentair Pool (right) presents Pentair Pool Step Into Swim sponsorship check to Rowdy Gaines, Vice President Partnerships and Development, PHTA, and Olympic Gold Medalist. As published on the Pentair Blog . ...
LONDON, UK / ACCESSWIRE / April 18, 2024 / Pentair plc (NYSE:PNR), a leader in helping the world sustainably move, improve and enjoy water, life's most essential resource, today released its 2023 Corporate Responsibility Report, reporting on the Company's efforts and progress toward Making Bett...
Lilly Completes Acquisition of POINT Biopharma PR Newswire INDIANAPOLIS , Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceuti...